Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS-wild type lung adenocarcinoma reveals gene signatures associated with patient outcome.

Summary, in English

In lung adenocarcinoma, EGFR and KRAS mutations dominate the mutational spectrum and have clear therapeutic implications. We sought to determine whether transcriptional subgroups of clinical relevance exist within EGFR-mutated, KRAS-mutated, or EGFR and KRAS-wild type (EGFRwt/KRASwt) adenocarcinomas.

• Author: Maria Planck; Sofi Isaksson; Srinivas Veerla; Johan Staaf
• Department/s: Breastcancer-genetics; Research Group Lung Cancer; BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
• Publishing year: 2013
• Language: English
• Pages: 5116-5126
• Publication/Series: Clinical Cancer Research
• Volume: 19
• Issue: 18
• Links: http://www.ncbi.nlm.nih.gov/pubmed/23938291?dopt=Abstract; http://dx.doi.org/10.1158/1078-0432.CCR-13-0928
• Document type: Journal article
• Publisher: American Association for Cancer Research
• Topic: Cancer and Oncology
• Status: Published
• Research group: Research Group Lung Cancer
• ISBN/ISSN/Other: ISSN: 1078-0432